All In Biotech

Drug Trial Radar · NCT07612813

A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults

A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adult Participants

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

18

Actual

Start

Jun 29, 2026

Primary completion

Sep 13, 2027

Study completion Sep 13, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
May 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and PK of AZD7760 when given as an intravenous (IV) infusion to healthy Japanese adult participants.

Conditions

  • Staphylococcus Aureus Bloodstream Infection

Interventions

  • AZD7760Drug

    Participants will receive AZD7760 via IV infusion.

  • PlaceboOther

    Participants will receive matching placebo via IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Adverse Events (AEs)Time frame: Day 1 to Day 181
  2. Occurrence of Medically-attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)Time frame: Day 1 to Day 361

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Sumida-ku, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.